Overgangsalderstudien - Effekter av ProGo for sunn aldring

Offentlig prosjektsammendrag

Prevention of adverse health effects associated with the menopause transition, is an area of unmet need with few validated nutraceutical interventions. The overarching goal of this project is to advance the development of a salmon protein hydrolysate (ProGo®) into a readily accessible and practical nutritional strategy that could potentially promote healthy metabolic function and body mass. 120 menopausal women who are overweight (not obese) but otherwise well will be included. They will be randomized to daily consumption of two different doses of ProGo® (2g or 4g) or a placebo (maltodextrine) for a duration of 16 weeks. The primary endpoint is change in BMI (body mass index) and secondaries including change in fat and lean mass, glucose metabolism, iron metabolism and inflammation, energy and vitality, and cognitive function and sleep quality.